Cargando…

Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial

INTRODUCTION: Tendon injury is a major cause of lameness and decreased performance in athletic equines. Various therapies for tendonitis have been described; however, none of these therapies results in complete tissue regeneration, and the injury recurrence rate is high even after long recovery peri...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, Armando de Mattos, Badial, Peres Ramos, Álvarez, Luis Emiliano Cisneros, Yamada, Ana Lucia Miluzzi, Borges, Alexandre Secorun, Deffune, Elenice, Hussni, Carlos Alberto, Garcia Alves, Ana Liz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854756/
https://www.ncbi.nlm.nih.gov/pubmed/23876512
http://dx.doi.org/10.1186/scrt236
_version_ 1782294854873645056
author Carvalho, Armando de Mattos
Badial, Peres Ramos
Álvarez, Luis Emiliano Cisneros
Yamada, Ana Lucia Miluzzi
Borges, Alexandre Secorun
Deffune, Elenice
Hussni, Carlos Alberto
Garcia Alves, Ana Liz
author_facet Carvalho, Armando de Mattos
Badial, Peres Ramos
Álvarez, Luis Emiliano Cisneros
Yamada, Ana Lucia Miluzzi
Borges, Alexandre Secorun
Deffune, Elenice
Hussni, Carlos Alberto
Garcia Alves, Ana Liz
author_sort Carvalho, Armando de Mattos
collection PubMed
description INTRODUCTION: Tendon injury is a major cause of lameness and decreased performance in athletic equines. Various therapies for tendonitis have been described; however, none of these therapies results in complete tissue regeneration, and the injury recurrence rate is high even after long recovery periods involving rest and physiotherapy. METHODS: A lesion was induced with collagenase gel in the superficial digital flexor tendon in the center portion of the metacarpal region of eight equines of mixed breed. After two weeks, the lesions of the animals in the treated and control groups were treated through the intralesional administration of mesenchymal stem cells derived from adipose tissue (adMSCs) suspended in platelet concentrate (PC) and with phosphate buffered saline (PBS), respectively. Serial ultrasound analyses were performed every two weeks. After 16 weeks of therapy, a biopsy was performed for histopathological, immunohistochemical and gene expression (type I collagen (COL1A1), type III collagen (COL3A1), tenascin-C (TNC), tenomodulin (TNMD), and scleraxis (SCX)) analyses. RESULTS: Differences in the ultrasound and histopathological analyses were observed between the groups. Improved results were reported in the group treated with adMSCs suspended in PC. There was no difference in the gene expression levels observed after the different treatments. The main results observed from the histopathological evaluation of the treated group were as follows: a prevention of the progression of the lesion, a greater organization of collagen fibers, and a decreased inflammatory infiltrate. A lack of progression of the lesion area and its percentage was observed in the ultrasound image, and increased blood flow was measured by Power Doppler. CONCLUSIONS: The use of adMSCs combined with PC for the therapy of experimentally induced tendonitis prevented the progression of the tendon lesion, as observed in the ultrasound examination, and resulted in a greater organization and decreased inflammation, as observed in the histopathological evaluation. These data demonstrate the therapeutic potential of this therapy for the treatment of equine tendonitis.
format Online
Article
Text
id pubmed-3854756
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38547562013-12-16 Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial Carvalho, Armando de Mattos Badial, Peres Ramos Álvarez, Luis Emiliano Cisneros Yamada, Ana Lucia Miluzzi Borges, Alexandre Secorun Deffune, Elenice Hussni, Carlos Alberto Garcia Alves, Ana Liz Stem Cell Res Ther Research INTRODUCTION: Tendon injury is a major cause of lameness and decreased performance in athletic equines. Various therapies for tendonitis have been described; however, none of these therapies results in complete tissue regeneration, and the injury recurrence rate is high even after long recovery periods involving rest and physiotherapy. METHODS: A lesion was induced with collagenase gel in the superficial digital flexor tendon in the center portion of the metacarpal region of eight equines of mixed breed. After two weeks, the lesions of the animals in the treated and control groups were treated through the intralesional administration of mesenchymal stem cells derived from adipose tissue (adMSCs) suspended in platelet concentrate (PC) and with phosphate buffered saline (PBS), respectively. Serial ultrasound analyses were performed every two weeks. After 16 weeks of therapy, a biopsy was performed for histopathological, immunohistochemical and gene expression (type I collagen (COL1A1), type III collagen (COL3A1), tenascin-C (TNC), tenomodulin (TNMD), and scleraxis (SCX)) analyses. RESULTS: Differences in the ultrasound and histopathological analyses were observed between the groups. Improved results were reported in the group treated with adMSCs suspended in PC. There was no difference in the gene expression levels observed after the different treatments. The main results observed from the histopathological evaluation of the treated group were as follows: a prevention of the progression of the lesion, a greater organization of collagen fibers, and a decreased inflammatory infiltrate. A lack of progression of the lesion area and its percentage was observed in the ultrasound image, and increased blood flow was measured by Power Doppler. CONCLUSIONS: The use of adMSCs combined with PC for the therapy of experimentally induced tendonitis prevented the progression of the tendon lesion, as observed in the ultrasound examination, and resulted in a greater organization and decreased inflammation, as observed in the histopathological evaluation. These data demonstrate the therapeutic potential of this therapy for the treatment of equine tendonitis. BioMed Central 2013-07-22 /pmc/articles/PMC3854756/ /pubmed/23876512 http://dx.doi.org/10.1186/scrt236 Text en Copyright © 2013 Carvalho et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Carvalho, Armando de Mattos
Badial, Peres Ramos
Álvarez, Luis Emiliano Cisneros
Yamada, Ana Lucia Miluzzi
Borges, Alexandre Secorun
Deffune, Elenice
Hussni, Carlos Alberto
Garcia Alves, Ana Liz
Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
title Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
title_full Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
title_fullStr Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
title_full_unstemmed Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
title_short Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
title_sort equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854756/
https://www.ncbi.nlm.nih.gov/pubmed/23876512
http://dx.doi.org/10.1186/scrt236
work_keys_str_mv AT carvalhoarmandodemattos equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT badialperesramos equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT alvarezluisemilianocisneros equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT yamadaanaluciamiluzzi equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT borgesalexandresecorun equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT deffuneelenice equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT hussnicarlosalberto equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial
AT garciaalvesanaliz equinetendonitistherapyusingmesenchymalstemcellsandplateletconcentratesarandomizedcontrolledtrial